BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Esterson YB, Flusberg M, Oh S, Mazzariol F, Rozenblit AM, Chernyak V. Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors. Clin Radiol. 2015;70:723-729. [PMID: 25921617 DOI: 10.1016/j.crad.2015.03.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Xiao YD, Ma C, Liu J, Li HB, Zhang ZS, Zhou SK. Evaluation of hypointense liver lesions during hepatobiliary phase MR imaging in normal and cirrhotic livers: is increasing flip angle reliable? Sci Rep 2016;6:18942. [PMID: 26732462 DOI: 10.1038/srep18942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Takatsu Y, Kobayashi S, Miyati T, Shiozaki T. A novel method for evaluating enhancement using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid in the hepatobiliary phase of magnetic resonance imaging. Clinical Imaging 2016;40:1112-7. [DOI: 10.1016/j.clinimag.2016.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yang M, Zhang Y, Zhao W, Cheng W, Wang H, Guo S. Evaluation of liver function using liver parenchyma, spleen and portal vein signal intensities during the hepatobiliary phase in Gd-EOB-D TPA-enhanced MRI. BMC Med Imaging 2020;20:119. [PMID: 33081713 DOI: 10.1186/s12880-020-00519-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ko JS, Byun J, Park S, Woo JY. Prediction of insufficient hepatic enhancement during the Hepatobiliary phase of Gd-EOB DTPA-enhanced MRI using machine learning classifier and feature selection algorithms. Abdom Radiol (NY) 2022;47:161-73. [PMID: 34647145 DOI: 10.1007/s00261-021-03308-0] [Reference Citation Analysis]
5 Cui E, Long W, Luo L, Hu M, Huang L, Chen X. Development and validation of a predictor of insufficient enhancement during the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging. Acta Radiol 2017;58:1174-81. [PMID: 28090793 DOI: 10.1177/0284185116687170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Sun XL, Jiang X, Kuang Y, Xing L, Bu LY, Yuan SH, Yu JM, Zheng SS. Potential of Gd-EOB-DTPA as an imaging biomarker for liver injury estimation after radiation therapy. Hepatobiliary Pancreat Dis Int 2019;18:354-9. [PMID: 31221569 DOI: 10.1016/j.hbpd.2019.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Takatsu Y, Nakamura M, Kobayashi S, Miyati T. Visual criterion for evaluating hepatobiliary phase image acquisition of gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid-enhanced MRI. Clinical Radiology 2018;73:760.e1-6. [DOI: 10.1016/j.crad.2018.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Jang HJ, Min JH, Lee JE, Shin KS, Kim KH, Choi SY. Assessment of liver fibrosis with gadoxetic acid-enhanced MRI: comparisons with transient elastography, ElastPQ, and serologic fibrosis markers. Abdom Radiol (NY) 2019;44:2769-80. [PMID: 31041497 DOI: 10.1007/s00261-019-02041-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Granata V, Fusco R, Avallone A, Catalano O, Filice F, Leongito M, Palaia R, Izzo F, Petrillo A. Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. Infect Agent Cancer 2017;12:23. [PMID: 28465718 DOI: 10.1186/s13027-017-0132-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
10 Huang X, Long L, Wei J, Li Y, Xia Y, Zuo P, Chai X. Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis. J Cancer Res Clin Oncol. 2019;145:2995-3003. [PMID: 31664520 DOI: 10.1007/s00432-019-03062-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
11 Furlan A, Borhani AA, Heller MT, Yu RK, Tublin ME. Non-focal liver signal abnormalities on hepatobiliary phase of gadoxetate disodium-enhanced MR imaging: a review and differential diagnosis. Abdom Radiol (NY) 2016;41:1399-410. [PMID: 26907715 DOI: 10.1007/s00261-016-0685-z] [Reference Citation Analysis]
12 Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS): Use of Gadoxetate Disodium and LI-RADS. J Magn Reson Imaging 2019;49:1236-52. [DOI: 10.1002/jmri.26540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
13 Takatsu Y, Nakamura M, Shiozaki T, Narukami S, Yoshimaru D, Miyati T, Kobayashi S. Assessment of the cut-off value of quantitative liver-portal vein contrast ratio in the hepatobiliary phase of liver MRI. Clin Radiol 2021;76:551.e17-24. [PMID: 33902888 DOI: 10.1016/j.crad.2021.03.015] [Reference Citation Analysis]
14 Imbriaco M, De Luca S, Coppola M, Fusari M, Klain M, Puglia M, Mainenti P, Liuzzi R, Maurea S. Diagnostic Accuracy of Gd-EOB-DTPA for Detection Hepatocellular Carcinoma (HCC): A Comparative Study with Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced Computed Tomography (CT). Pol J Radiol. 2017;82:50-57. [PMID: 28217239 DOI: 10.12659/pjr.899239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
15 Xiao YD, Ma C, Liu J, Li HB, Zhou SK, Zhang ZS. Transient severe motion during arterial phase in patients with Gadoxetic acid administration: Can a five hepatic arterial subphases technique mitigate the artifact? Exp Ther Med 2018;15:3133-9. [PMID: 29456716 DOI: 10.3892/etm.2018.5760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Takatsu Y, Nakamura M, Kobayashi S, Miyati T. Prediction of Sufficient Liver Enhancement on the Gadoxetate Disodium-enhanced Hepatobiliary Phase Imaging Using Transitional Phase Images and Albumin-bilirubin Grade. Magn Reson Med Sci 2021;20:152-9. [PMID: 32461506 DOI: 10.2463/mrms.mp.2020-0050] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Rao SX, Wang J, Wang J, Jiang XQ, Long LL, Li ZP, Li ZL, Shen W, Zhao XM, Hu DY, Zhang HM, Zhang L, Huan Y, Liang CH, Song B, Zeng MS. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodium. J Dig Dis 2019;20:54-61. [PMID: 30693659 DOI: 10.1111/1751-2980.12707] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
18 Takatsu Y, Kobayashi S, Miyati T, Shiozaki T. Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system. Eur J Radiol 2016;85:2206-10. [PMID: 27842668 DOI: 10.1016/j.ejrad.2016.10.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wu JW, Yu YC, Qu XL, Zhang Y, Gao H. Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity. World J Gastroenterol 2018; 24(3): 415-423 [PMID: 29391764 DOI: 10.3748/wjg.v24.i3.415] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kobi M, Paroder V, Flusberg M, Rozenblit A, Chernyak V. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase? Clinical Radiology 2017;72:55-62. [DOI: 10.1016/j.crad.2016.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]